Arcutis Biotherapeutics (ARQT) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Arcutis Biotherapeutics (ARQT) is implementing cloud-based AI to automate data collection in dermatological research. Demand for skin treatments remains stable, rendering the business virtually independent of macroeconomic trends. However, promotion costs for Zoryve and insurance risks are weighing on profits. The current EV/EBITDA multiple on the GURU.Markets chart shows that the indicator stands at 90.55.

Arcutis Biotherapeutics Inc - ARQT Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/14/2026)

Metric breakdowns and analytics for Arcutis (ARQT)

- market price and analyst price targets:

Price Chart arcutis.com|ARQT - Analyst Median Target

- market capitalization details:

Market Value Arcutis Biotherapeutics|ARQT - Enterprise Value

- book value of equity indicators:

Book Value per Share Arcutis Biotherapeutics|ARQT - Book Valuation of Business|Market Value to Book Value Ratio arcutis.com|ARQT - Total Business Assets

- issuer credit burden and liquidity indicators:

- financial results and valuation multiples details:

ARQT - Profit After Payment of Taxes|Projected Future Earnings Arcutis Biotherapeutics|ARQT - Business Payback Period|Future Price to Earnings Arcutis|ARQT - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Arcutis|ARQT - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Arcutis Biotherapeutics|ARQT - Earnings per share for the last twelve months|Quarterly EPS earnings growth arcutis.com|ARQT - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Arcutis Biotherapeutics

- sales volume and revenue indicators:

ARQT - Company Total Revenue|Company Future Sales Volume Arcutis Biotherapeutics Inc|ARQT - Market Cap to Sales Volume|Forward P/S Multiple Arcutis

Summary company analysis:arcutis.com ARQT

Product sample of Arcutis Biotherapeutics, Inc.

The scaling of ZORYVE therapy commercialization is directly reflected in the EV/EBITDA chart, allowing for an assessment of the business's market value inclusive of net debt. This indicator compares the total cost of acquiring the asset with operating profit before depreciation and amortization, determining the investment payback period and the level of financial stability for Arcutis Biotherapeutics (ARQT) during periods of volatility.

Competitors of Arcutis Biotherapeutics (ARQT)

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization krystalbio.com KRYS|Total Company Value to Operating Income Before Depreciation Ratio apogeetherapeutics.com (APGE)|VCEL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ORKA - EV/EBITDA Multiple|SMTI: EV/EBITDA Multiple|DBVT - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Solesence|Enterprise Value to Operating Income Before Depreciation DERM (journeymedicalcorp.com)|EV/EBITDA Multiple FBRX|EMPG - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization sol-gel.com SLGL|AXIL: Enterprise Value to Operating Income Before Depreciation|Medicus Pharma - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation VRCA (Verrica Pharmaceuticals Inc.)|HOTH: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio BFRI (Biofrontera Inc)|Enterprise Value to EBITDA Ratio VYNE|Enterprise Value to EBITDA Ratio Sonoma Pharmaceuticals (SNOA)|Enterprise Value to EBITDA Ratio QNRX (Quoin Pharmaceuticals Ltd)|EV/EBITDA Multiple Azitra (AZTR)|EV/EBITDA Multiple DRMA (dermatarx.com)|Business Value to Operating Income Before Depreciation ELAB|RVNC: Enterprise Value to EBITDA Ratio